Pharmacogenetics of morphine: Potential implications in sickle cell disease

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American journal of hematology/oncology

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.21027PMID 17722074
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current evidence for a genetic modulation of the response to analgesics

  2006cited by this paper
• Circumstances of death in adult sickle cell disease patients

  2006cited by this paper
• Clinical response to morphine in cancer patients and genetic variation in candidate genes

  2005cited by this paper
• The Val158Met polymorphism of the human catechol‐O‐methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients

  2005cited by this paper
• The 118 A > G polymorphism in the human µ‐opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease

  2004cited by this paper
• Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice.

  2004cited by this paper
• A novel functional polymorphism in the uridine diphosphate–glucuronosyltransferase 2B7 promoter with significant impact on promoter activity

  2004cited by this paper
• Analgesic effects of morphine and morphine‐6‐glucuronide in a transcutaneous electrical pain model in healthy volunteers

  2003cited by this paper
• A pharmacogenetic study of uridine diphosphate–glucuronosyltransferase 2B7 in patients receiving morphine

  2003cited by this paper
• Systemic Exposure to Morphine and the Risk of Acute Chest Syndrome in Sickle Cell Disease

  2003cited by this paper
• COMT val158met Genotype Affects µ-Opioid Neurotransmitter Responses to a Pain Stressor

  2003cited by this paper
• Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients

  2003cited by this paper
• A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans.

  2002cited by this paper
• Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy

  2002cited by this paper
• Contribution of Morphine‐6‐Glucuronide to Antinociception following Intravenous Administration of Morphine to Healthy Volunteers

  2002cited by this paper
• The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.

  2002cited by this paper
• Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.

  2002cited by this paper
• Regulation of μ-Opioid Receptor Gene Transcription by Interleukin-4 and Influence of an Allelic Variation within a STAT6 Transcription Factor Binding Site*

  2001cited by this paper
• Judging the effectiveness of analgesia for children and adolescents during vaso-occlusive events of sickle cell disease.

  2000cited by this paper
• Opiate-induced Analgesia Is Increased and Prolonged in Mice Lacking P-glycoprotein

  2000cited by this paper
• Enhanced morphine analgesia in mice lacking beta-arrestin 2.

  1999cited by this paper
• Molecular tinkering of G protein‐coupled receptors: an evolutionary success

  1999cited by this paper
• mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality.

  1998cited by this paper
• Hepatic function as assessed by lidocaine metabolism in sickle cell disease.

  1998cited by this paper
• Human UGT2B7 catalyzes morphine glucuronidation.

  1997cited by this paper
• Pharmacokinetics of Opioids in Renal Dysfunction

  1996cited by this paper
• Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene

  1996cited by this paper
• Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease.

  1995cited by this paper
• Pain from sickle-cell crisis.

  1995cited by this paper
• Mortality in sickle cell disease. Life expectancy and risk factors for early death.

  1994cited by this paper
• Death from a morphine infusion during a sickle cell crisis.

  1993cited by this paper
• Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.

  1993cited by this paper
• The maturation of morphine clearance and metabolism.

  1992cited by this paper
• Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation.

  1992cited by this paper
• Transfusion-related chronic liver disease in sickle cell anemia.

  1991cited by this paper
• Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine‐6‐glucuronide

  1990cited by this paper
• Morphine-3-Glucuronide — A potent antagonist of morphine analgesia

  1990cited by this paper
• Renal abnormalities in sickle cell disease.

  1990cited by this paper
• Oral morphine in cancer pain: influences on morphine and metabolite concentration

  1990cited by this paper
• Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys.

  1987cited by this paper
• Opioid Pharmacokinetics in Relation to their Effects

  1987cited by this paper
• Relationship between plasma morphine concentrations and pharmacologic effects in postoperative patients using patient-controlled analgesia.

  1985cited by this paper
• Clinical consequences of acquired transfusional iron overload in adults.

  1981cited by this paper
• The liver in sickle cell disease: A clinicopathologic study of 70 patients*

  1980cited by this paper
• Inheritance of low erythrocyte catechol-o-methyltransferase activity in man.

  1977cited by this paper
• Structural aspects of the active site of cytochrome P-450cam.

  1973cited by this paper

• Pharmacogenomics and Opioid Efficacy in Sickle Cell Disease

  2026influential citation
• Precision, integrative medicine for pain management in sickle cell disease

  2023cites this paper
• Unlike Morphine, Long-Term Exposure to Analgesic Mitragynine, 7-Hydroxymitragynine, Paynantheine, and Speciociliatine Alkaloids Does Not Contribute to Antinociceptive Tolerance of μ-Opioid Receptors

  2020cites this paper
• Opioid treatment for acute and chronic pain in patients with sickle cell disease.

  2020cites this paper
• Effect of chronic opioid therapy on pain and survival in a humanized mouse model of sickle cell disease.

  2019cites this paper
• Sensitization of nociceptors and dorsal horn neurons contributes to pain in sickle cell disease.

  2019cites this paper
• The role of metabolites in morphine analgesic effects

  2019cites this paper
• A Glimpse into Pharmacogenomics in Africa

  2019cites this paper
• Early initiation of inhaled corticosteroids does not decrease acute chest syndrome morbidity in pediatric patients with sickle cell disease.

  2018cites this paper
• Codeine influences the serum and urinary profile of endogenous androgens but does not interact with the excretion rate of administered testosterone.

  2018cites this paper
• Current Non-HSCT Treatments for SCD

  2018cites this paper
• Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis

  2017cites this paper
• Key Pharmacogenomic Considerations for Sickle Cell Disease Patients

  2017cites this paper
• Clinical Implications of Opioid-Induced Hyperalgesia

  2016cites this paper
• An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine

  2016cites this paper
• Crises vaso-occlusives en Guadeloupe : anthropologie d'une prise en charge de la douleur

  2015cites this paper
• Drépanocytose et douleur chez l’enfant : description et prise en charge antalgique des crises vaso-occlusives

  2014cites this paper
• Envisioning the future in symptom science.

  2014cites this paper
• Cytochrome P450 2D6 Polymorphisms and Predicted Opioid Metabolism in African American Children With Sickle Cell Disease

  2013cites this paper
• Methadone Prescribing in the Sickle Cell Patient

  2013cites this paper
• A potent oral P‐selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease

  2012cites this paper
• Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: Study protocol for a randomised controlled trial

  2012cites this paper
• Carbon-fiber microelectrode amperometry reveals sickle-cell-induced inflammation and chronic morphine effects on single mast cells.

  2012cites this paper
• Genotypic screening of the main opiate‐related polymorphisms in a cohort of 139 sickle cell disease patients

  2012cites this paper
• La crise drépanocytaire : une urgence douloureuse

  2012cites this paper
• Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher‐risk myelodysplastic syndromes

  2011cites this paper
• ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children

  2011cites this paper
• Pain management in children and adolescents with sickle cell disease

  2011cites this paper
• Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease

  2011cites this paper
• Hepcidin in anemia of chronic heart failure

  2011cites this paper
• Methotrexate‐induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis

  2011cites this paper
• Multiple myeloma and pregnancy

  2011cites this paper
• Quality of life in thalassemia: A comparison of SF‐36 results from the thalassemia longitudinal cohort to reported literature and the US norms

  2011cites this paper
• Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura

  2011cites this paper
• International working group for myelofibrosis research and treatment response assessment and long‐term follow‐up of 50 myelofibrosis patients treated with thalidomide‐prednisone based regimens

  2011cites this paper
• [Patient controlled analgesia in children].

  2010cites this paper
• Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids.

  2010cites this paper
• L'analgésie autocontrôlée ou PCA chez l'enfant

  2010cites this paper
• Pain management in adults with sickle cell disease in a medical center emergency department.

  2010cites this paper
• Can Heterogeneity of Chronic Sickle-Cell Disease Pain Be Explained by Genomics? A Literature Review

  2009influential citation
• How to use drugs for pain management: from pharmacokinetics to pharmacogenomics

  2008cites this paper
• Variations in opioid responsiveness.

  2008cites this paper
• Clinical report

  2008cites this paper